Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Chronic Spontaneous Urticaria · Asthma

Novartis India

Novartis Pharmaceuticals

Novartis India clinical programs — 341 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Mumbai, IN HQ
1996 Founded
2,240 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Mumbai, IN
Founded
1996
Employees
2,240
Programs
341
Drugs
317
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Novartis India projects

341 ClinicalTrials.gov programs sponsored by Novartis India.

Novartis India has 341 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

341 programs

Clinical programs

Page 6 of 8

  1. LCZ696

    Novartis Pharmaceuticals

    Hypertension

    phase 2 small molecule completed

    2 trials

  2. LDE225 0.75%

    Novartis Pharmaceuticals

    Sporadic Superficial and Nodular Skin Basal Cell Carcinomas

    phase 2 small molecule terminated

    1 trial

  3. LIK066

    Novartis Pharmaceuticals

    Obese Patients With Non-alcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial

  4. LNA043

    Novartis Pharmaceuticals

    Osteoarthritis

    phase 2 small molecule active

    1 trial

  5. MAS825, -

    Novartis Pharmaceuticals

    Still’s disease

    phase 2 small molecule active

    1 trial

  6. Midostaurin

    Novartis Pharmaceuticals

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  7. Nilotinib followed by treatment-free

    Novartis Pharmaceuticals

    Chronic Myelogenous Leukemia

    phase 2 small molecule completed

    1 trial

  8. Osilodrostat

    Novartis Pharmaceuticals

    Cushing's Syndrome

    phase 2 small molecule completed

    1 trial

  9. PHE885

    Novartis Pharmaceuticals

    Multiple Myeloma

    phase 2 mab terminated

    1 trial

  10. PPY988A

    Novartis Pharmaceuticals

    Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in participants already treated with GT005 in the previous studies GT005-01 (FOCUS), GT005-02 (EXPLORE) and GT005-03 (HORIZON).

    phase 2 small molecule active

    1 trial

  11. Panobinostat

    Novartis Pharmaceuticals

    Classical Hodgkin's Lymphoma

    phase 2 small molecule completed

    1 trial

  12. Patupilone

    Novartis Pharmaceuticals

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  13. QBW251

    Novartis Pharmaceuticals

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial

  14. Rapcabtagene autoleucel

    Novartis Pharmaceuticals

    ANCA Associated Vasculitis (AAV)

    phase 2 mab active

    1 trial

  15. SODIUM CHLORIDE , DII235

    Novartis Pharmaceuticals

    Cardiovascular risk reduction in participants with elevated Lp(a)

    phase 2 small molecule active

    1 trial

  16. Scemblix 40 mg film-coated tablets

    Novartis Pharmaceuticals

    CML-CP or CML-AP patients with T315I mutation

    phase 2 small molecule active

    1 trial

  17. Seasonal flu vaccine

    Novartis Pharmaceuticals

    Seasonal Influenza

    phase 2 mab completed

    1 trial

  18. Serelaxin

    Novartis Pharmaceuticals

    Acute Heart Failure

    phase 2 small molecule completed

    1 trial

  19. TISAGENLECLEUCEL

    Novartis Pharmaceuticals

    High-risk B-cell acute lymphoblastic leukemia

    phase 2 small molecule active

    1 trial

  20. TISAGENLECLEUCEL

    Novartis Pharmaceuticals

    Adult patients with refractory or relapsed follicular lymphoma

    phase 2 small molecule active

    1 trial

  21. Vi-CRM197 vaccine

    Novartis Pharmaceuticals

    Typhoid Fever

    phase 2 mab completed

    1 trial

  22. alb-interferon alfa 2b

    Novartis Pharmaceuticals

    Chronic Hepatitis C

    phase 2 small molecule completed

    1 trial

  23. cyclosporine (reduced exposure) / everolimus

    Novartis Pharmaceuticals

    Kidney Transplantation

    phase 2 small molecule completed

    1 trial

  24. eltrombopag

    Novartis Pharmaceuticals

    Thrombocytopaenia

    phase 2 small molecule completed

    1 trial

  25. rapcabtagene autoleucel

    Novartis Pharmaceuticals

    Scleroderma, Diffuse

    phase 2 mab active

    1 trial

  26. zigakibart

    Novartis Pharmaceuticals

    Immunoglobulin A Nephropathy (IgAN)

    phase 2 mab active

    1 trial

  27. 68Ga-NNS309

    Novartis Pharmaceuticals

    Pancreatic Ductal Adenocarcinoma

    phase 1 small molecule active

    1 trial

  28. A phase I study of [177Lu]Lu-EVS459 in patients with ovarian and lung cancers

    Novartis Pharmaceuticals

    Advanced high-grade serous ovarian cancer (OC), Locally advanced unresectable or metastatic non-squamous non-small cell lung carcinoma (NSCLC)

    phase 1 other active

    1 trial

  29. CAAA601A52101

    Novartis Pharmaceuticals

    Glioblastoma

    phase 1 other active

    1 trial

  30. CAAA603C12101

    Novartis Pharmaceuticals

    Glioblastoma

    phase 1 other active

    1 trial

  31. CAAA617A12101

    Novartis Pharmaceuticals

    Metastatic Castration-Resistant Prostate Cancer

    phase 1 small molecule active

    1 trial

  32. CADPT01C12101

    Novartis Pharmaceuticals

    Advanced or metastatic BRAF V600 colorectal cancer.

    phase 1 other active

    1 trial

  33. CAIN457E22101

    Novartis Pharmaceuticals

    Polymyalgia rheumatica (PMR), Giant cell arteritis (GCA)

    phase 1 other active

    1 trial

  34. CDAK539A12102

    Novartis Pharmaceuticals

    Patients with advanced malignancies

    phase 1 other active

    1 trial

  35. CDAK539A12103

    Novartis Pharmaceuticals

    Advanced Malignancies and Hepatic Impairment

    phase 1 other active

    1 trial

  36. CDFF332A12101

    Novartis Pharmaceuticals

    Advanced, relapsed Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  37. CDKY709A12101C

    Novartis Pharmaceuticals

    Nasopharyngeal Carcinoma, Triple Negative Breast Cancer, Microsatellite Stable Colorectal Cancer, Non-Small Cell Lung Cancer, Cutaneous Melanoma

    phase 1 other active

    1 trial

  38. CDLX313A12101

    Novartis Pharmaceuticals

    Parkinson’s Disease

    phase 1 other active

    1 trial

  39. CEGF816X2102

    Novartis Pharmaceuticals

    Patients with EGFR-mutant Non Small Cell Lung Cancer

    phase 1 other active

    1 trial

  40. CFKL480A02101

    Novartis Pharmaceuticals

    Advanced breast cancer and advanced NSCLC

    phase 1 other active

    1 trial

  41. CFXX489A12101

    Novartis Pharmaceuticals

    Locally advanced or metastatic unresectable colorectal cancer (CRC), Locally advanced unresectable or metastatic breast cancer (BC), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC)

    phase 1 other active

    1 trial

  42. CGCJ904A12101

    Novartis Pharmaceuticals

    Locally advanced unresectable or metastatic colorectal cancer (CRC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic soft tissue sarcoma (excluding GIST and Kaposi sarcoma), Locally advanced unresectable or metastatic HR+/HER2- ductal or lobular breast cancer (BC), Locally advanced unresectable or metastatic triple negative breast cancer (TNBC)

    phase 1 other active

    1 trial

  43. CHJB647A02101

    Novartis Pharmaceuticals

    Heart failure (HF)

    phase 1 other active

    1 trial

  44. CIAG933A12101

    Novartis Pharmaceuticals

    Advanced mesothelioma or other solid tumors harboring certain molecular alterations in the Hippo pathway

    phase 1 other active

    1 trial

  45. CIDH305X2101

    Novartis Pharmaceuticals

    Advanced malignancies that harbor IDH1R132 mutations

    phase 1 other active

    1 trial

  46. CINE963A02103

    Novartis Pharmaceuticals

    Malaria

    phase 1 other active

    1 trial

  47. CKFA115A12101

    Novartis Pharmaceuticals

    Thymic Carcinoma, Nasopharyngeal Cancer, Anal Cancer, Head and Neck Squamous Cell Carcinoma, Epithelial Ovarian Cancer, Cutaneous melanoma, Mesothelioma, Non-small cell lung cancer, Esophagogastric Cancer, Triple negative breast cancer, Microsatellite Instability High Colorectal Cancer, Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  48. CLDK378A2120C

    Novartis Pharmaceuticals

    Non-small cell lung cancer

    phase 1 other active

    1 trial

Frequently asked questions

How many clinical projects does Novartis India have?

341 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.